25 July 2017
Oxford BioMedica: Notice of Interim Results
Results date: 17 August 2017
Oxford, UK – 25 July 2017: Oxford BioMedica plc (LSE: OXB) (“OXB” or “the Group”), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2017 on Thursday 17 August 2017.
A briefing for analysts will be held at 09:30 GMT on 17 August 2017 at 1 Cornhill, London, EC3V 3ND. There will be a simultaneous live conference call with Q&A and the presentation will be available on the Group’s website at www.oxfordbiomedica.co.uk. An audio replay file will be made available shortly afterwards.
Please contact Consilium Strategic Communications for further details.
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Financial PR Enquiries: Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal / Philippa Gardner / Laura Thornton
Consilium Strategic Communications
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.